Replies to post #229303 on Cytodyn Inc (CYDY)

[kgromax]

Antonio Migliarese has resigned!
Every past resignation has revealed bad Cytodyn news in the following weeks.
What will come with Antonio's departure?

[fung_derf]

Well you are an interesting poster.....I'm curious why you had nothing to say around the time the CEO was accused of fraud. No anger? Frustration? Defense? No thoughts to the other shareholders when they needed to hear something positive?

Reading the news you posted I found a couple things worth discussing...

Dr. Lalezari’s appointment as CEO was made following a robust and competitive search process, carried out by the Company’s Board of Directors over the past seven months with support from international search advisers.[color=red][/color]

CytoDyn Board Chair Tanya Urbach, commented, “Since July 2023, CytoDyn’s board has undertaken a thorough and highly competitive process to identify our next CEO, considering several qualified candidates in detail. Following his appointment as interim CEO in November 2023, a consensus developed by the board that Dr. Lalezari was the outstanding candidate and is the right leader for CytoDyn at this time. We are pleased that he has agreed to assume the longer-term role and continue to lead us during this critical time.”

Dr. Lalezari stated, “I am honored to accept the position of CEO during this crucial transition period for CytoDyn. Our clinical protocol in HIV+ subjects with immune activation has been revised per FDA guidance and, assuming the removal of the current hold on the trial protocol, we hope to initiate the trial this year.”

In addition, the Company announced that Mitchell Cohen has been appointed to the role of interim CFO, effective February 1, 2024, following the resignation of Antonio Migliarese, effective January 31, 2024. Mr. Cohen will be working with Mr. Migliarese to facilitate a smooth transition over the next several weeks.

A robust and competitive search??? Then they settled on the guy who was already there?? Sounds like their search didn't have many candidates. Maybe you know who the others were?

Then, "assuming the removal"....I call this "penny stock speak".....these penny stock companies are always "planning to" or "hope to" .....rarely do you see a PR stating they actually did something. Wouldn't you agree?

I will say, Mitch seems like an interesting hire.....

About
Founded in 1997, Athenian Venture Partners is a venture capital firm specializing in early stage investments in IT+Healthcare

[Monroe1]

Buying...." Mr. Cohen has more than 30 years of financial, operations and general business experience as a senior financial and operations executive at various public and private companies and has extensive expertise in all SEC and public company matters. Mr. Cohen also has experience in public accounting with an emphasis on financial audits of hedge funds and mergers and acquisitions engagements. Prior to joining CytoDyn, Mr. Cohen served as interim Chief Financial Officer for several NASDAQ-listed companies, including Blue Apron Holdings, Inc., Redbox Entertainment, Inc., and Cerence Inc. Before that, he was a consulting Chief Financial Officer for various companies, and served as CFO of Athenian Venture Partners, a venture capital firm specializing in early-stage investments in information technology, healthcare, and digital health. Prior roles also include interim senior Chief Financial Officer at CIFC LLC; C-level roles at S2BN Entertainment, Inc.; and, Chief Financial Officer and Secretary of Asta Funding, Inc. Mr. Cohen graduated from Queens College with a bachelor’s degree in accounting and economics."

And just what I said I hoped would happen.... Dr. J .... permanent CEO!!!

$CYDY$ 2024